Literature DB >> 15160243

[Best supportive care of pancreatic carcinoma].

K Schoppmeyer1, J Mössner.   

Abstract

The incidence of pancreatic cancer is about 10,000 cases a year in Germany. The role of surgery as a curative modality is limited. The 5-year survival for all stages remains less than 5%. Pain, cachexia, jaundice, nausea, fatigue and depression are frequent symptoms which reduce the quality of life for affected patients. Therefore, amelioration of symptoms is a major goal of palliative care. Chemotherapy may yield a moderate survival benefit. Gemcitabine is the drug of choice in metastatic pancreatic cancer. In locally advanced disease, radiochemotherapy can be considered. Different treatment strategies against molecular targets are currently tested in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15160243     DOI: 10.1007/s00108-004-1222-7

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  35 in total

1.  Is prophylactic gastrojejunostomy indicated for unresectable periampullary cancer? A prospective randomized trial.

Authors:  K D Lillemoe; J L Cameron; J M Hardacre; T A Sohn; P K Sauter; J Coleman; H A Pitt; C J Yeo
Journal:  Ann Surg       Date:  1999-09       Impact factor: 12.969

2.  Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale.

Authors:  Giuseppe Colucci; Francesco Giuliani; Vittorio Gebbia; Maria Biglietto; Piergiorgio Rabitti; Generoso Uomo; Silvio Cigolari; Antonio Testa; Evaristo Maiello; Massimo Lopez
Journal:  Cancer       Date:  2002-02-15       Impact factor: 6.860

3.  Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.

Authors:  T J Littlewood; E Bajetta; J W Nortier; E Vercammen; B Rapoport
Journal:  J Clin Oncol       Date:  2001-06-01       Impact factor: 44.544

4.  [Radiochemotherapy with gemcitabine and cisplatin in pancreatic cancer -- feasible and effective].

Authors:  Ralf Wilkowski; Martin Thoma; Volker Heinemann; Horst-Günter Rau; Andreas Wagner; Clemens Stoffregen; Eckhart Dühmke
Journal:  Strahlenther Onkol       Date:  2003-02       Impact factor: 3.621

5.  Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

Authors:  Jordan D Berlin; Paul Catalano; James P Thomas; John W Kugler; Daniel G Haller; Al Bowen Benson
Journal:  J Clin Oncol       Date:  2002-08-01       Impact factor: 44.544

6.  [Operative management in the treatment of pancreatic cancer].

Authors:  L Fischer; H Friess; K Z'graggen; W Uhl; M W Büchler
Journal:  Zentralbl Chir       Date:  2003-05       Impact factor: 0.942

7.  Assessment of weight loss, food intake, fat metabolism, malabsorption, and treatment of pancreatic insufficiency in pancreatic cancer.

Authors:  M M Perez; A D Newcomer; C G Moertel; V L Go; E P Dimagno
Journal:  Cancer       Date:  1983-07-15       Impact factor: 6.860

8.  A prospective, randomized, controlled trial of metal stents for malignant obstruction of the common bile duct.

Authors:  K Knyrim; H J Wagner; J Pausch; N Vakil
Journal:  Endoscopy       Date:  1993-03       Impact factor: 10.093

Review 9.  Aprepitant--a novel NK1-receptor antagonist.

Authors:  Lisa Patel; Celeste Lindley
Journal:  Expert Opin Pharmacother       Date:  2003-12       Impact factor: 3.889

10.  Changes in nutritional status associated with unresectable pancreatic cancer.

Authors:  S J Wigmore; C E Plester; R A Richardson; K C Fearon
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.